| pubmed-article:19880436 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19880436 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:19880436 | lifeskim:mentions | umls-concept:C0280100 | lld:lifeskim |
| pubmed-article:19880436 | lifeskim:mentions | umls-concept:C1136012 | lld:lifeskim |
| pubmed-article:19880436 | lifeskim:mentions | umls-concept:C1883254 | lld:lifeskim |
| pubmed-article:19880436 | lifeskim:mentions | umls-concept:C2355512 | lld:lifeskim |
| pubmed-article:19880436 | lifeskim:mentions | umls-concept:C0920321 | lld:lifeskim |
| pubmed-article:19880436 | lifeskim:mentions | umls-concept:C0679622 | lld:lifeskim |
| pubmed-article:19880436 | lifeskim:mentions | umls-concept:C0205314 | lld:lifeskim |
| pubmed-article:19880436 | lifeskim:mentions | umls-concept:C2936926 | lld:lifeskim |
| pubmed-article:19880436 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:19880436 | pubmed:dateCreated | 2010-2-23 | lld:pubmed |
| pubmed-article:19880436 | pubmed:abstractText | Sagopilone (ZK-EPO) is a fully synthetic microtubule-stabilizing agent that has demonstrated high antitumor activity in preclinical models. This first-in-human phase I study aimed to determine the maximum tolerated dose (MTD) and dose-limiting toxic effects (DLTs) of 3-weekly sagopilone treatment. | lld:pubmed |
| pubmed-article:19880436 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19880436 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19880436 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19880436 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19880436 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19880436 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19880436 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19880436 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19880436 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:19880436 | pubmed:issn | 1569-8041 | lld:pubmed |
| pubmed-article:19880436 | pubmed:author | pubmed-author:SchmidPP | lld:pubmed |
| pubmed-article:19880436 | pubmed:author | pubmed-author:ThielEE | lld:pubmed |
| pubmed-article:19880436 | pubmed:author | pubmed-author:ReidMM | lld:pubmed |
| pubmed-article:19880436 | pubmed:author | pubmed-author:PossingerKK | lld:pubmed |
| pubmed-article:19880436 | pubmed:author | pubmed-author:WiesingerHH | lld:pubmed |
| pubmed-article:19880436 | pubmed:author | pubmed-author:KorfelAA | lld:pubmed |
| pubmed-article:19880436 | pubmed:author | pubmed-author:LindemannSS | lld:pubmed |
| pubmed-article:19880436 | pubmed:author | pubmed-author:GiurescuMM | lld:pubmed |
| pubmed-article:19880436 | pubmed:author | pubmed-author:KiewePP | lld:pubmed |
| pubmed-article:19880436 | pubmed:author | pubmed-author:KühnhardtDD | lld:pubmed |
| pubmed-article:19880436 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19880436 | pubmed:volume | 21 | lld:pubmed |
| pubmed-article:19880436 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19880436 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19880436 | pubmed:pagination | 633-9 | lld:pubmed |
| pubmed-article:19880436 | pubmed:meshHeading | pubmed-meshheading:19880436... | lld:pubmed |
| pubmed-article:19880436 | pubmed:meshHeading | pubmed-meshheading:19880436... | lld:pubmed |
| pubmed-article:19880436 | pubmed:meshHeading | pubmed-meshheading:19880436... | lld:pubmed |
| pubmed-article:19880436 | pubmed:meshHeading | pubmed-meshheading:19880436... | lld:pubmed |
| pubmed-article:19880436 | pubmed:meshHeading | pubmed-meshheading:19880436... | lld:pubmed |
| pubmed-article:19880436 | pubmed:meshHeading | pubmed-meshheading:19880436... | lld:pubmed |
| pubmed-article:19880436 | pubmed:meshHeading | pubmed-meshheading:19880436... | lld:pubmed |
| pubmed-article:19880436 | pubmed:meshHeading | pubmed-meshheading:19880436... | lld:pubmed |
| pubmed-article:19880436 | pubmed:meshHeading | pubmed-meshheading:19880436... | lld:pubmed |
| pubmed-article:19880436 | pubmed:meshHeading | pubmed-meshheading:19880436... | lld:pubmed |
| pubmed-article:19880436 | pubmed:meshHeading | pubmed-meshheading:19880436... | lld:pubmed |
| pubmed-article:19880436 | pubmed:meshHeading | pubmed-meshheading:19880436... | lld:pubmed |
| pubmed-article:19880436 | pubmed:meshHeading | pubmed-meshheading:19880436... | lld:pubmed |
| pubmed-article:19880436 | pubmed:meshHeading | pubmed-meshheading:19880436... | lld:pubmed |
| pubmed-article:19880436 | pubmed:meshHeading | pubmed-meshheading:19880436... | lld:pubmed |
| pubmed-article:19880436 | pubmed:meshHeading | pubmed-meshheading:19880436... | lld:pubmed |
| pubmed-article:19880436 | pubmed:meshHeading | pubmed-meshheading:19880436... | lld:pubmed |
| pubmed-article:19880436 | pubmed:meshHeading | pubmed-meshheading:19880436... | lld:pubmed |
| pubmed-article:19880436 | pubmed:meshHeading | pubmed-meshheading:19880436... | lld:pubmed |
| pubmed-article:19880436 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:19880436 | pubmed:articleTitle | Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors. | lld:pubmed |
| pubmed-article:19880436 | pubmed:affiliation | Hammersmith Early Clinical Trials Unit, Charing Cross Hospital, Imperial College London, London, UK. p.schmid@imperial.ac.uk | lld:pubmed |
| pubmed-article:19880436 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19880436 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:19880436 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:19880436 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
